➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,550,780

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,550,780 protect, and when does it expire?

Patent 9,550,780 protects AUSTEDO and is included in one NDA.

Protection for AUSTEDO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has nineteen patent family members in ten countries.

Summary for Patent: 9,550,780
Title:Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Inventor(s): Sommer; Andreas (Carlsbad, CA), Zhang; Chengzhi (San Diego, CA), Carter; John (Vista, CA), Arthur; John (Vista, CA), Bradbury; Margaret (Vista, CA), Gant; Thomas (Carlsbad, CA), Shahbaz; Manouchehr (San Diego, CA)
Assignee: Auspex Pharmaceuticals, Inc. (LaJolla, CA)
Application Number:15/071,797
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 9,550,780

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-001 Apr 3, 2017 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-002 Apr 3, 2017 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-003 Apr 3, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,550,780

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013318182 ⤷  Free Forever Trial
Australia 2018222896 ⤷  Free Forever Trial
Australia 2020205297 ⤷  Free Forever Trial
Brazil 112015005894 ⤷  Free Forever Trial
Canada 2883641 ⤷  Free Forever Trial
Canada 3124804 ⤷  Free Forever Trial
China 104684555 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.